Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2016-03-23 M&A Activity
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
PHARMAGEST: External growth on the home hospitalisation market
M&A Activity Classification · 1% confidence The document is dated March 23, 2016, and is explicitly labeled as a "PRESS RELEASE." The content details a significant corporate action: the acquisition of DICSIT by MALTA INFORMATIQUE (a subsidiary of PHARMAGEST Group). This type of announcement, detailing M&A activity, is typically released via a press release before or concurrently with a formal regulatory filing. Since the text describes the transaction, its rationale, and key figures, it fits the description of a corporate action announcement. Among the provided codes, 'TAR' (M&A Activity) is the most specific fit for an acquisition announcement. It is not a full 10-K, an earnings release (ER), or a proxy statement. It is not merely announcing a report's publication (RPA), as it contains substantial, specific details about the transaction itself.
2016-03-23 English
PHARMAGEST : Croissance externe
M&A Activity Classification · 1% confidence The document announces a significant corporate action: the acquisition of DICSIT by MALTA INFORMATIQUE (a subsidiary of Groupe PHARMAGEST). This involves changes in ownership structure (100% acquisition of shares) and governance (MALTA INFORMATIQUE becoming a SAS à conseil d'administration). This type of event, detailing fundraising, financing activities, or capital structure changes (specifically M&A activity leading to a change in control/structure), aligns best with the 'Capital/Financing Update' category. While it is an M&A event, the provided categories do not have a specific M&A code, but 'TAR' is defined as 'Merger proposals or takeover bids'. Since this is a completed acquisition announcement detailing the strategic rationale and financial impact, it fits the spirit of TAR, but the change in corporate structure and financing activity is also highly relevant. Given the focus on the acquisition and the resulting structural change, 'CAP' (Capital/Financing Update) is a strong candidate, but 'TAR' (M&A Activity) is more precise for an acquisition announcement. I will select TAR as it directly addresses the core event described: an acquisition/takeover.
2016-03-23 French
PHARMAGEST: strategic partnership between TELUS & Domedic
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and details a strategic partnership agreement between two companies (TELUS Health and Groupe DOmedic Inc., a PHARMAGEST Group subsidiary). It announces a business development, an investment, and the integration of technological platforms. This content is characteristic of a corporate announcement regarding business strategy, partnerships, or financing, rather than a formal regulatory filing like a 10-K, an earnings report (ER), or a detailed management discussion (MDA). Since it announces a significant business event (partnership/investment), it fits best under Capital/Financing Update (CAP) if the focus is on the investment aspect, or potentially Regulatory Filings (RNS) if it's a general market disclosure. Given the focus on a strategic alliance and investment leading to capital structure change (PHARMAGEST retains 26% after TELUS investment), 'CAP' is a strong candidate, but 'RNS' is often used for general press releases announcing material non-financial events. However, the text heavily implies a change in corporate structure/financing related to the partnership. Since 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes,' and an investment is explicitly mentioned, CAP is the most specific fit among the options for a material business development announcement that isn't purely financial results or governance.
2016-03-18 English
PHARMAGEST : partenariat stratégique entre TELUS Santé & DO
Regulatory Filings Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a strategic partnership between Groupe DOmedic Inc. (a subsidiary of PHARMAGEST) and TELUS Santé. It details the nature of the partnership, technological integrations, and includes forward-looking financial calendar information for PHARMAGEST. This type of announcement, detailing a significant business event (partnership/alliance) but not being a full financial report (like 10-K or IR) or a formal regulatory filing for a specific event (like DVA or DIV), fits best under the general category of a business update or announcement. Since there is no specific code for a 'Press Release' or 'Business Update', and the content is a formal announcement of a strategic development, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for non-standard, material announcements, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is a strategic announcement. Given the nature of announcing a strategic alliance, RNS is the best fit as a general regulatory/material announcement fallback.
2016-03-18 French
Pharmagest - 2015 Turnover
Earnings Release Classification · 1% confidence The document is titled "PRESS RELEASE" and provides a summary of the company's consolidated unaudited turnover for the full year 2015 (€113.47 million) compared to 2014, broken down by quarter and new business divisions. It highlights key financial figures, business segment performance, and provides an outlook. This structure—a press release announcing preliminary or summary financial results for a period—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), as it explicitly states the turnover is 'unaudited' and focuses on highlights and divisional performance before the full results publication date (April 4, 2016). FY 2015
2016-02-11 English
PHARMAGEST : chiffre d'affaires 2015
Earnings Release Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and is dated February 11, 2016. It presents the consolidated, unaudited revenue ('Chiffre d'affaires') for the full year 2015, broken down by quarter and by new business divisions. It discusses financial performance, strategic positioning, and provides a financial calendar mentioning the 'Publication des résultats annuels 2015' (Publication of 2015 annual results) on April 4, 2016. Since this document is an initial announcement summarizing key financial highlights for a period (the full year 2015) and is explicitly labeled as a press release, it fits the definition of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) nor is it a mere announcement of a future report (RPA), as it contains the actual results. FY 2015
2016-02-11 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.